FTC antitrust policies should be more transparent, biomedical industry reps urge Pitofsky.
This article was originally published in The Tan Sheet
Executive Summary
FTC ANTITRUST POLICIES SHOULD BE MORE TRANSPARENT FOR BIOMEDICAL industries, an attorney suggested at an Oct. 23 meeting between pharmaceutical and biotech reps and Federal Trade Commission Chairman Robert Pitofsky. The session was part of a 10-week schedule of FTC Hearings on "Global and Innovation-Based Competition" first promised by Pitofsky at his Jan. 19 confirmation hearing. The meetings are to "evaluate whether all aspects of antitrust and consumer protection policies are up-to-date in today's world."